Clinical Trials Logo

Hyperthermia, Malignant clinical trials

View clinical trials related to Hyperthermia, Malignant.

Filter by:
  • None
  • Page 1

NCT ID: NCT04287556 Recruiting - Clinical trials for Hyperthermia, Malignant

Population at Risk of Malignant Hyperthermia: Ambispective Cohort.

Start date: February 26, 2020
Phase:
Study type: Observational

Malignant hyperthermia (MH) is a pharmacogenetic disease that manifests itself as a hypermetabolic response of skeletal musculature, in genetically susceptible patients, with the inhalation of volatile halogenated anesthetics, depolarizing neuromuscular relaxants such and, rarely, physical stressors such as intense exercise and heat stroke. HM diagnosis is based on the performance of two tests: - In vitro muscle contraction test (IVCT): it is the gold standard of the diagnosis of HM in Europe. - Pharmacogenetic study: about 50 genetic variants associated with HM have been described. It also has been described that B lymphocytes of patients with MH have metabolic alterations. The main objective is to evaluate the association of disorders that occur with hypermetabolic response of skeletal musculature and susceptibility to malignant hyperthermia (MH).